Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 225

1.

Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance.

Akuta N, Suzuki F, Kobayashi M, Hosaka T, Fujiyama S, Kawamura Y, Sezaki H, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25238. [Epub ahead of print]

PMID:
29896794
2.

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment who Developed Inclusion Body Myositis.

Kuwano T, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Intern Med. 2018 Mar 30. doi: 10.2169/internalmedicine.0585-17. [Epub ahead of print]

3.

Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial.

Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K.

Hepatol Res. 2018 Mar 30. doi: 10.1111/hepr.13075. [Epub ahead of print]

PMID:
29601141
4.

Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

Akuta N, Toyota J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H.

J Gastroenterol. 2018 Mar 2. doi: 10.1007/s00535-018-1445-3. [Epub ahead of print]

PMID:
29500489
5.

Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.

Ogata F, Akuta N, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 Jun;90(6):1087-1093. doi: 10.1002/jmv.25047. Epub 2018 Feb 26.

PMID:
29427443
6.

Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies.

Akuta N, Watanabe C, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.

Hepatol Commun. 2017 Feb 27;1(1):46-52. doi: 10.1002/hep4.1019. eCollection 2017 Feb.

7.

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.

Ohya K, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Kominami Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 May;90(5):919-925. doi: 10.1002/jmv.25023. Epub 2018 Jan 30.

PMID:
29315652
8.

Usefulness of virtual touch quantification for staging liver fibrosis in patients with hepatitis C, and factors affecting liver stiffness measurement failure compared with liver biopsy.

Tsukano N, Miyase S, Saeki T, Mizobe K, Iwashita H, Arima N, Fujiyama S.

Hepatol Res. 2018 Apr;48(5):373-382. doi: 10.1111/hepr.13041. Epub 2018 Jan 15.

PMID:
29226524
9.

Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome.

Fujiyama S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.

BMC Gastroenterol. 2017 Oct 25;17(1):112. doi: 10.1186/s12876-017-0668-8.

10.

Cholangiolocellular Carcinoma in a Young Patient Who Showed Sustained Virological Response after Treatment for Hepatitis C Virus Infection.

Osawa M, Saitoh S, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kinowaki K, Fujii T, Fukusato T, Kondo F, Kumada H.

Intern Med. 2017 Nov 15;56(22):3033-3040. doi: 10.2169/internalmedicine.9021-17. Epub 2017 Sep 25.

11.

Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.

Ogasawara N, Kobayashi M, Akuta N, Kominami Y, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Suzuki F, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H.

J Med Virol. 2018 Feb;90(2):313-319. doi: 10.1002/jmv.24950. Epub 2017 Sep 25.

PMID:
28906010
12.

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Dig Dis Sci. 2017 Oct;62(10):2932-2942. doi: 10.1007/s10620-017-4739-z. Epub 2017 Sep 7.

PMID:
28884320
13.

Correction for Zhao et al., "Corepressive Action of CBP on Androgen Receptor Transactivation in Pericentric Heterochromatin in a Drosophila Experimental Model System".

Zhao Y, Takeyama KI, Sawatsubashi S, Ito S, Suzuki E, Yamagata K, Tanabe M, Kimura S, Fujiyama S, Ueda T, Murata T, Matsukawa H, Shirode Y, Kouzmenko AP, Li F, Tabata T, Kato S.

Mol Cell Biol. 2017 Aug 28;37(18). pii: e00355-17. doi: 10.1128/MCB.00355-17. Print 2017 Sep 15. No abstract available.

14.

Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.

Osawa M, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Suzuki Y, Ikeda K, Kumada H.

J Med Virol. 2017 Dec;89(12):2144-2148. doi: 10.1002/jmv.24890. Epub 2017 Aug 31.

PMID:
28667756
15.

New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease.

Kawamura Y, Ikeda K, Arase Y, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H.

Intern Med. 2017;56(12):1459-1465. doi: 10.2169/internalmedicine.56.7830. Epub 2017 Jun 15.

16.

Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.

Ogata F, Kobayashi M, Akuta N, Osawa M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.

Oncology. 2017;93(2):92-98. doi: 10.1159/000470910. Epub 2017 Apr 28.

PMID:
28448999
17.

Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride.

Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K.

Hepatol Res. 2018 Jan;48(1):45-50. doi: 10.1111/hepr.12894. Epub 2017 Apr 19.

PMID:
28322485
18.

The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.

Sezaki H, Suzuki F, Hosaka T, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

Liver Int. 2017 Sep;37(9):1325-1333. doi: 10.1111/liv.13384. Epub 2017 Mar 17.

PMID:
28178397
19.

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.

Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2017 Jul;89(7):1248-1254. doi: 10.1002/jmv.24767. Epub 2017 Feb 27.

PMID:
28079269
20.

Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma.

Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Kobayashi M, Ikeda K, Kumada H.

BMC Gastroenterol. 2016 Dec 12;16(1):141.

Supplemental Content

Loading ...
Support Center